Drug Profile
ME 1111
Alternative Names: ME-1111Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Meiji Seika Pharma
- Class Antifungals; Cresols; Pyrazoles; Skin disorder therapies; Small molecules
- Mechanism of Action Succinate cytochrome c oxidoreductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Onychomycosis
Most Recent Events
- 14 Feb 2020 Meiji Seika Pharma completes a phase II trial in Onychomycosis in Japan (Topical) (JapicCTI183840)
- 01 Feb 2018 Phase-II clinical trials in Onychomycosis in Japan (Topical) (JapicCTI183840)
- 01 Feb 2018 Meiji Seika Pharma plans a phase II trial for Onychomycosis in Japan (JapicCTI183840)